Financial reports
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
1 Nov 23
10-Q
2023 Q2
Quarterly report
2 Aug 23
10-K/A
2022 FY
Annual report (amended)
19 May 23
10-Q
2023 Q1
Quarterly report
3 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
22 Feb 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
1 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
Current reports
8-K
Submission of Matters to a Vote of Security Holders
16 Feb 24
8-K
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
7 Dec 23
8-K
Cerevel Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
1 Nov 23
8-K
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
12 Oct 23
8-K
Results of Operations and Financial Condition
11 Oct 23
8-K
Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
2 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 23
8-K
Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer
10 May 23
8-K
Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results
3 May 23
8-K
Cerevel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
22 Feb 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
12 Oct 23
424B5
Prospectus supplement for primary offering
11 Oct 23
S-8
Registration of securities for employees
22 Feb 23
S-3
Shelf registration
8 Nov 22
424B5
Prospectus supplement for primary offering
12 Aug 22
424B5
Prospectus supplement for primary offering
12 Aug 22
424B5
Prospectus supplement for primary offering
10 Aug 22
S-3
Shelf registration
10 May 22
S-8
Registration of securities for employees
1 Mar 22
POS AM
Prospectus update (post-effective amendment)
10 Nov 21
Proxies
DEFA14A
Additional proxy soliciting materials
9 Feb 24
DEFM14A
Proxy related to merger
18 Jan 24
PRER14A
Preliminary revised proxy
18 Jan 24
PREM14A
Preliminary proxy related to merger
5 Jan 24
DEFA14A
Additional proxy soliciting materials
7 Dec 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEFA14A
Additional proxy soliciting materials
28 Apr 21
Other
EFFECT
Notice of effectiveness
21 Nov 22
CORRESP
Correspondence with SEC
16 Nov 22
UPLOAD
Letter from SEC
10 Nov 22
EFFECT
Notice of effectiveness
26 May 22
CORRESP
Correspondence with SEC
20 May 22
UPLOAD
Letter from SEC
20 May 22
EFFECT
Notice of effectiveness
23 Nov 21
EFFECT
Notice of effectiveness
18 Nov 21
CORRESP
Correspondence with SEC
18 Nov 21
UPLOAD
Letter from SEC
18 Nov 21
Ownership
4
N ANTHONY COLES
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
N ANTHONY COLES
6 Mar 24
4
N ANTHONY COLES
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
29 Feb 24
4
JOSEPH EDELMAN
21 Feb 24
5
Gabrielle Sulzberger
13 Feb 24
4
John Renger
8 Feb 24
4
N ANTHONY COLES
8 Feb 24